Thus we hypothesized that targeting of the PEA3 and/or Notch pathways might provide a new therapeutic strategy for triple-negative breast cancer as well as possibly other breast cancer subtypes where PEA3 regulates Notch-1 and/or Notch-4. Here, NOTCH1 is linked to breast cancer.